Table 1.

Endpoints in a clinical study by Borges et al., 2020 [91].

Indicator	Results after >15 Days of Therapy	The Experimental Group (with Methisoprinol)		Control Group (without Methisoprinol)		Statistically Significant Risk Ratio ≤ 0.57
Clinical Picture	With Clinical Signs	3/30	(10%)	20/30	(66.6%)	0.14
Oxygen Saturation	SO2 > 90%	30/30	(100%)	23/30	(76.6%)	0.0
PCR Test	PCR Negative	28/30	(93.3%)	20/30	(66.6%)	0.20
Axial Tomography	No Lung Lesions	29/30	(96.6%)	4/30	(13.3%)	0.038

Note: The data obtained were analyzed and presented as frequency (F) and percentage (%); the correlation was established using relative risk, considering statistically significant differences when the RR value is equal to or less than 0.57, with the results expressed in Table 1 [84].